Azor (Amlodipine Bes/Olmesartan Med) Patent Expiration, LOE Window & CMS Spending

Azor (Amlodipine Bes/Olmesartan Med) by Cosette: Off-Patent Genericized (AB Competition), 9 AB generics, $2.9M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCosette
FDA Application & PathwayN022100 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$2.9M
2024 Medicare Part D Spend$2.9M
2024 Medicaid Spend$17K
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 32.9% 2-yr change)